This is a preview of subscription content, log in via an institution to check access.
Notes
2020 US dollars
Reference
van Boemmel-Wegmann S, et al. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. JCO Oncology Practice : OP2100140, 6 Jul 2021. Available from: URL: http://doi.org/10.1200/OP.21.00140
Rights and permissions
About this article
Cite this article
Ipilimumab-based first-line melanoma therapies among most costly in the USA. PharmacoEcon Outcomes News 883, 22 (2021). https://doi.org/10.1007/s40274-021-7893-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7893-7